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A mutation at amino acid 511 changes R to T, and produces a cleavage defective HIV 
envelope (gpl60) which arrests the process of binding and entry trapping possible critical 
neutralizing epitopes for a future vaccine candidate.
Director: Jack H. Nunberg
Human immunodeficiency virus type-1 (HIV-1) is a retrovirus and the primary etiological 
agent of acquired immunodeficiency syndrome (AIDS). The main focus of HIV vaccine 
research is on the viral envelope due to the critical role it plays in binding and entry 
events. The HIV-1 envelope is produced as a polypeptide precursor protein (gp 160) 
which is cleaved by host cell proteases into the biologically active envelope. Cleavage 
occurs at the carboxyl side of gpl20 at the highly basic sequence (REKR) called sitel.
We have constructed a cleavage defective gp 160 HIV-1 ENV by mutating arginine at the 
carboxyl terminis of gpl20 to threonine in the 168P wild type HIV envelope. Western 
blots were prepared fi-om HIVIG immunoprecipated (IP) lystates and supernatants of 
R51 IT transfected Cos 7 cells. These western blots provided evidence the R51 IT 
polypeptide precursor protein is not cleaved. Lysates produced immunoreactive bands 
corresponding to the precursor polyprotein gp 160 while little to no gpl20 was shed into 
supernatants. Mutant envelope was produced in equivalent quantities to that of 168P 
wildtype envelope in transfected Cos 7 cells. Surface expression of R51 IT was 
determined by FACS analysis and Immunofluorescence assay (IFA).
R51 IT has the capability of interacting with CD4 and coreceptor yet fusion is inhibited 
because the hydrophobic N-terminal fusion peptide remains attached to the C-terminis of 
gpl20. The fusion assay. Vaccinia Lac Z reporter system and Pseudotype assays showed 
R511T did not support cell-cell fusion or viral infectivity. R51 IT essentially fi*eezes the 
binding events before the prehairpin intermediate is formed and after interaction with CD4 
and coreceptor (figure 1). The cleavage defective mutant R51 IT is a candidate for a 
future transgenic mouse vaccine study. A formaldehyde fixed fusion-competent vaccine 
would trap R511T in binding conformations that arrise before the formation of the 
prehairpin intermediate. If critical neutralizing epitopes arrise we can map them to 
binding events after interaction with CD4/coreceptor and before the prehairpin 
intermediate. A non-formaldehyde fixed fusion-competent vaccine would trap the 
cleavage defective mutant and could be used to ask if critical neutralizing epitopes arrise 
where fusion events are stopped.
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1. INTRODUCTION
Human immunodeficiency virus type-1 (HIV-1) is a retrovirus and the etiological 
agent of acquired immunodeficiency syndrome (AIDS) (1-4). There is no known cure 
for HIV infection, limited effective therapy and no protective vaccine. At the end of 1998, 
NIAID (National Institute of Allergy and Infectious Diseases) estimated that 33.4 million 
adults and children were living with HIV/AIDS with 22.5 million infected in sub-Saharan 
Afi-ica. (50) Michael Merson, AIDS chief of WHO (World Health Organization) projects 
that by the year 2000, forty million people will be infected with HIV (7,31). The need for 
a vaccine that is effective against HIV-1 is urgent since the virus continues to spread 
worldwide (8). The main focus for HIV vaccine research has been on the envelope 
glycoprotein (gpl20) due to the important role it plays in binding and viral entry into host 
cells. In 1993, the National Institutes of Health sponsored phase I and II clinical trials 
using two recombinant (HIV) gpl20 subunits. The obstacle in this and other vaccine 
studies has been the failure to develop antibodies that neutralize infection by virus 
obtained from infected patients, i.e. primary isolates (PI) (8,9,11,12,30). Recently a 
“fusion-competent” HIV vaccine which captured the transient envelope-CD4-coreceptor 
during the binding events was used to immunize transgenic mice. Antibodies capable of 
neutralizing infectivity of 23 out of 24 primary HIV isolates were generated (10).
During the binding and entry events, the env-CD4-coreceptor undergo many 
conformational changes exposing previously unexposed epitopes within the complex of 
interacting receptors. A fusion competent vaccine catches those epitopes in their exposed 
conformation long enough to be surveyed by the immune system for immunogenicity.
1-1. HIV Envelope Glycoprotein Synthesis and Processing
HIV surface glycoproteins are synthesized as an inactive precursor polyprotein and 
processed in the secretory pathway of infected host cells. A 4.3 kb spliced mRNA is 
co-translationally transferred into the lumen of the endoplasmic reticulum (ER) as a 
90-kDa envelope precursor polypeptide (15,17). During co-translational transfer into 
the lumen of the ER, cellular enzymes begin modifying the polypeptide by adding 
N-asparagine-linked oligomannosyl carbohydrate residues. These added residues 
represent up to 50% of the molecular weight of the immature envelope glycoprotein 
(gp 160) (15,25-27). The N-linked glycans added to the gp 41 portion, located on the 
C-terminis of gpl60, appear to play an important role in efficient intracellular transport 
and processing of gpl60. Those gpl60 envelope molecules lacking N-linked glycans on 
the gp 41 portion, show reduced cleavage and are retained in the oligomeric state at the 
medial face of the golgi apparatus. The exact reason for this arrest is unknown (13). 
While in the ER, gpl60 forms nine intramolecular disulfide bonds, then the folded gpl60 
monomers associate into oligomeric complexes containing three folded gpl60 molecules 
per complex (14,17-20,27,49).
After approximately two hours in the ER, the gpl 60 oligomers are then 
transferred to the golgi apparatus where further processing occurs. In the cis and medial 
cistemae of the golgi apparatus, oligomeric gpl 60 is modified by mannose trimming and 
cleaved by the cellular serine proteases furin and PC7 (15, 19,20,). Proteolytic cleavage 
is necessary to produce a biologically functional HIV envelope (14). Cleavage occurs at 
a highly conserved basic region (REKR), at a site termed “site 1” located in the 
C-terminal region of gpl60. Cleavage at sitel liberates the N-terminis of gp 41 firom
the C-terminis of gpl 20. This cleavage event is thought to induce conformational 
changes that bury the N-terminal hydrophobic region on gp 41 called the fusion peptide 
(36). Within the C-terminal region of gp 41 there is a stretch of hydrophobic amino acids 
that transverses the plasma membrane one time and “anchors” the mature HIV envelope to 
the surface of virions and infected cells. The second cleavage product, gpl 20, is 
non-covalently associated near both its C and N termini with the extra cellular portion of 
the transmembrane gp 41 “anchor” protein (19, 15 ). The maturing envelope then 
moves to the late medial and trans cistemae of the golgi apparatus where extensive 
complex carbohydrate modification of gpl 20 takes place. The mature HIV envelope 
(gp 120/gp41 complex) is then shuttled to the host cell plasma membrane by the cellular 
vesicle transport system and incorporated into budding virions (15). The bonding 
between gp41 and gpl20 is somewhat unstable and some of the gpl20 subunit is “shed” 
into the extra cellular medium. The significance of gp 120 shedding into the extra cellular 
medium is not known (19,27,36).
Cleavage of gpl 60 is relatively inefficient, only 5-15% of gpl 60 are cleaved and 
then transported to the surface as mature HIV envelope. The 85-95% of misfolded and 
uncleaved gpl 60 is transferred to cellular lysosomes where it is degraded (18).
1-2. Cleavage sites
The amino acid (a.a.) region 500-523 in gpl 60 contains two potential cleavage 
sequences, basic-X-basic-basic. The majority of oligomerized gpl 60 is cleaved on each 
chain of gpl 60 at the carboxyl side of sitel (REKR). After cleavage at site one, gp 41 
remains as an oligomer and proceeds through the golgi presenting as the biologically 
active complex. Approximately 10-20% of oligomerized gpl 60 is cleaved on each chain
of gpl 60 at the carboxyl side of site 2 (KAKR). Cleavage at site two results in envelope 
that is not biologically active. Both sites are located in close proximity to each other with 
site 2 cleaving after a.a. 503 and site 1 cleaving after a.a. 511 (figure 1). The basic amino 
acids of site 2 play an unknown, but required role for cleavage at site 1 (16,19,23,29). A 
third cleavage site has been reported by furin at a generally basic region in the V3 loop of 
gpl 20. Relevance of cleavage in the V3 loop is not understood. Virion associated gpl 20 
is not cleaved at the V3 site suggesting that this site is not accessible during normal 
processing (23).
Location of cleavage sites at the C-terminus of gpl20
gpl20/gp4l 
cleavage site 
site 2 site 1 1
5 ’- A P T K A K R  R V V Q R E K R  - 3 ’
Î Î
503 511
Figure 1. Diagram of the amino acid sequence encompassing cleavage sitel and site 2 on 
the C-terminus of gpl 20. Cleavage site 2 plays a critical yet unknown role for cleavage 
to occur at site 1 and produces a non-biologically active envelope.
1-3. HIV-1 Envelope Glycoprotein Attachment and Entry
There are three proteins involved in the binding and entry process. The mature 
HIV envelope protein attaches to cellular CD4 which results in a cascade of 
conformational changes that recruits the HIV coreceptor located on the host cell surface. 
After docking of the coreceptor, further conformational changes occur that ends in the 
pH-independent membrane fusion between host cell and virion. (35,36)
Attachment occurs when gpl20 binds with high afBnity interaction to -12 amino 
acids in the first domain of the host cell CD4 receptor. The CD4 receptor is present in 
high concentrations on the surface of T-helper lymphocytes and in lower concentrations 
on the macrophages/monocyte lineages (3,31,33-34,36,46). Binding of the mature HIV 
envelope to the CD4 increases both disassociation (or shedding) of the gp 120 subunit and 
exposure of certain previously unexposed epitopes including the binding site for an HIV 
coreceptor. (3,27,46,47).
Fusion between virion and host cell requires both binding to host cell CD4 and 
interaction with a second human accessory factor called a coreceptor. In 1996, Edward 
A. Berger, chief of the molecular structure section at NIAID reported on the discovery of 
the long sought after coreceptor required for HIV to penetrate T-helper lymphocytes. 
Today this HIV coreceptor is known as CXCR4 ( 51 ). Two months later five separate 
research teams reported on CCR5 as the coreceptor required for HIV penetration of 
monocyte/macrophages. These HIV coreceptors are seven-transmembrane G 
Protein-coupled receptors that bind chemokines released in the body. Chemokines are 
small cellular proteins that recruit leukocytes to sites of inflammation (3, 27,39,51,58).
It may be helpful to follow each step represented in the current model for 
envelope mediated binding and entry (figure 2). Following recruitment of the coreceptor 
into what is now a ‘‘tri-molecular complex” made up of ENV-CD4-coreceptor, the 
hydrophobic stretch at the N-terminis called the “fusion peptide” of gp41 becomes 
exposed and (59,37) is thought to penetrate the host cell plasma membrane 
(27,38,41,53). This early fusion-active conformation has been trapped by using inhibitory 
synthetic peptides to regions in gp41 only exposed during the fiision event. This 
inhibitoiy peptide binds to the coiled coil region of gp41 at an undefined point during 
conformational changes following attachment of gpl 20 to CD4 and coreceptor. Binding 
of the inhibitory peptide captures both gp41 and gpl 60 during receptor-induced 
conformational changes (38,43). After placement of the “fusion peptide” into the host 
cell membrane, a core structure of gp41 is formed which consists of a six helix bundle, 
formed by an internal triple-stranded coiled coil with three anti-parallel helices packing in 
the groves (38). This hairpin intermediate is thought to draw the viral and plasma 
membranes close enough for membrane fusion.
1-4. Research Goal
The goal of this project was to arrest HIV binding events in an attempt to trap 
critical neutralizing epitopes for a future vaccine candidate. The research described in this 
thesis focuses on producing and characterizing a cleavage defective mutant HIV envelope 
protein that arrests HIV binding events. By mutating R to T at the carboxyl side of site 1 
(REKR) in the 168P wild type HIV envelope plasmid, a cleavage defective ENV is 
produced (R511T). This R511T envelope can be expressed on surfaces of transfected 
cells or pseudotyped virions where it binds but does not support fusion. It has been
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previously published that R51 IT mutant gpl60 can be pulled down using CD4 covalently 
attached to sepharose beads in a competitive fashion. (53) It has also been shown that 
gpl60 binds both CD4 and coreceptor. An s-peptide tagged coreceptor which binds to 
S-agarose was used to pull down the gpl60-CD4 complex (Meg Trahey, unpublished). 
We believe R51 IT binds CD4 and coreceptor but does not have the capacity to form the 
pre-hairpin intermediate (figure 2). In R511T, the fusion peptide remains attached to the 
C-terminis of gpl 20. Conformational changes are arrested in the R511 T-CD4-coreceptor 
complex at an undefined point before the pre-hairpin intermediate is formed. An 
inhibitory peptide that binds to the C-proximal a-helix of gp41 in the CD4-coreceptor 
bound wild type envelope, also co-precipitates CD4-coreceptor bound gp 160. This 
finding suggests the C-proximal a-helix of gp41 becomes exposed or partially exposed 
before the pre-hairpin intermediate is formed. It also suggests uncleaved precursor 
envelope undergoes the initial receptor-induced conformational changes similar to 
wildtype envelope (38). A formaldehyde fixed, “fusion-competent” vaccine (10) made 
using R511T will help map possible neutralizing epitopes if they arise during R511T 
binding events. In the absence of formaldehyde, the fusion-competent vaccine using 
R51 IT would trap possible neutralizing epitopes at the undefined point were binding 
events are arrested before the pre-hairpin intermediate.
HIV envelope mediated binding and entry events
Virion envelope 
protein trimer
CD4 binding
gpl20
gp41
Fusion
complete
Hairpin
intermediate
CD4 and CoR 
binding
Pre-hairpin
intermediate
Figure 2. The current model o f envelope mediated binding and fusion. The initial step in 
binding and entiy involves the virion envelope protein trimer binding to host cell CD4 
(step 1). This envelope-CD4 interaction produces conformational changes within the 
complex that 6cilitate binding o f the HIV coreceptor located on the host cell plasma 
membrane to the envelope-CD4 complex (step 2). Following binding of envelope 
protein to the CD4 and coreceptor, major conformational changes must occur to expose 
gp41 (step 3) and allow the N-terminal fusion peptide to be inserted into the host cell 
membrane (step 4). This pre-hairpin intermediate contains two a-helical regions which 
collapse into a six helix bundle called the hairpin intermediate (step 5). This collapse is 
thought to bring the viral and cell membranes close enough for membrane fusion (step 6). 
R51 IT arrests these binding events at an undefined point during the major conformational 
changes prior to exposure of the gp4I N-terminis between step 3 and 4 of the current 
model (54). The N-terminal “fusion peptide” is not cleaved firom the C-terminis o f gp 120 
preventing advancement of viral entry.
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1-5 Specific Aims
1. Primers were designed which substituted R at site 511 with T (R51 IT) and 
introduced a Pstl restriction endonuclease digestion site in the wild type HIV-1 envelope 
168? plasmid. The QuikChange™ site-directed mutagenesis kit (Stratagene) was used to 
introduce the mutations described above. Initial screening for plasmid DNA containing 
the R51 IT was performed by Pstl restriction endonuclease digestion. Sequence analysis 
performed by Joan Strange (The Murdock Molecular Biology Laboratory, University of 
Montana) confirmed the substitution.
2. Surface expression of R51 IT envelope on transfected Cos 7 cells was shown by 
Fluorescence activated cell sorter (FACS) (with the help of Joann York) and 
Immunofluorescence assay (IFA).
3. To characterize envelope fimction, both cell-cell fusion and viral infectivity were 
assessed. Cell-cell fusin was assessed through the fusion assay and confirmed by the 
vaccinia lacZ reporter gene assay (vaccinia experiment was done by Joann York who is 
properly vaccinated to work with vaccinia virus. All procedures were carried out under 
biosafety conditions appropriate for class 2 agents). Viral infectivity was assessed by the 
pseudotype assay.
4. Envelope proteins were immunoprecipitated (IP) fi*om both transfected Cos 7 cell 
lysates and cell fi*ee supernatant using HIVIG (polyclonal antibody prepared firom pooled 
sources of HIV-1 infected plasma) (10) and protein A sepharose.
5. Western blots of the IP samples were probed using 50.1 (a mouse monoclonal 
antibody specific for the sequence Arg-Ile-His-Ile-Gly in the V3 loop) (57) followed by 
anti-mouse conjugated biotin then avadin-horse radish peroxidase. Blots were visualized
11
by chemiluminescence using the ECL detection kit (Amersham life science). This protein 
characterization confirmed that R51 IT protein is cleavage defective and little to no gpl20 
is shed into the supernatant.
12
2. MATERIALS AND METHODS
2-1. Plasmids, mutations, initial screening
The QuikChange,™ Site-Directed Mutagenesis kit was used according to the 
manu&ctures instructions to introduce the mutation at amino acid 511. The amino acid R 
was substituted by T in the primary cleavage site REKR to REKT in the wild type 168? 
envelope plasmid (56). 168? virus was obtained from the Amsterdam Cohort 
(ACH168.10; 168?) (9). ?rimers for QuikChange™ were synthesized by Joan Strange 
(The Murdock Molecular Biology Laboratory, University of Montana).
substitution of R to T at amino acid 511 was made in such a way as to introduce a 
Pstl site to facilitate initial screening. The oligonucleotides (figure 6a) are complimentary 
to the opposite strands of 168? wildtype plasmid and both containing the desired change.
The linear amplification reaction mixture included a 1:10 dilution of reaction 
buffer provided with the kit, 150 ng of 168? wild type plasmid DNA, 125 ng of each 
oligonucleotide primer (containing the R to T mutation and Pstl site described above) 
and 1 ul of dNT? mix provided with the kit in a total volume of 50 ul. Solution was 
mixed gently then 2.5 Units of Pfu DNA polymerase was added from the kit which 
replicates both plasmid strands with high fidelity without displacing mutant 
oligionucleotide primers (figure 3 ). Conditions used for the substitution included 16 
total cycle reactions at the following temperatures (?erkin Elmer gene amp system 9600): 
Ramping at 96® C for 0.5 min then 16 cycles of 95® C at 0.5 min, 55® C at 1 min, 68® C 
for 16.46 min. (2 minutes/kb of plasmid length of 8.23 kb as described in Quikchange 
kit.) Linear amplification results in a mix of mutated plasmids with staggered nicks and 
parental plasmids. Reaction product was treated with 1.5 units Dpn I restriction enzyme
13
for 2.5 hours at 37® C. Dpn I endonuclease is specific for methylated and hemimethylated 
DNA and efiFectively digests parental strands of 168P wild type plasmid DNA but not the 
newly synthesized mutated plasmid.
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QuikChange™ Site directed mutagenesis method
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Figure 3. Overview of the QuikChange™ site directed mutagenesis method. (Step 1) 
Plasmid containing the envelope gene and site for mutation was purified. (Step 2) 
Plasmid was denatured then primers containing the desired mutation were annealed to the 
complimentary site on the plasmid and extended by Pfu polymerase resulting in nicked 
circular strands. (Step 3) Methylated non-mutated parental strands were digested with 
Dpn I. (Step 4) Transformed E. coli repair nick in vivo.
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2-2. Amplification, quantification and sequencing
Epicuhan coli XL!-blue superoompetent cells (Stratagene) were thawed on ice in 
15 ml Falcon 2059 polypropylene tubes then treated with y^mercaptoethanol at a final 
concentration of 25 mM, then incubated on ice for 10 minutes. The ^mercaptoethanol 
increases transfection 2-3 fold. Approximately 50 ng R511T DNA was added to the 
cells and incubated for 30 minutes on ice. E. co//-plasmid DNA mixture was heat pulsed 
at 42° C for precisely 45 seconds, then incubated on ice for another 2 minutes. Preheated, 
42° C SOC medium (59) in a volume o f900 ul was added to transformed bacterial cells 
followed by incubation at 37° C for 1 hour with shaking at 250 rpm. Three volumes of 
50,100 and 200 ul of transformed bacterial cells were plated on LB agar (59) containing 
50 ug/ml ampicillin then incubated at 37° C overnight. R511T plasmid carries the gene for 
y^lactamase which hydrolyzes ampicillin and allows E. coli carrying the mutant plasmid to 
grow in the presence of ampicillin. Single colonies were grown in 3 ml of LB containing 
100 ug/ml ampicillin over night then the plasmid was isolated for initial screening fi’om 
1.5 ml of overnight culture by using a modified miniprep protocol (37). Restriction 
endonuclease digestion on plasmid DNA using Pstl produced bands of expected sizes for 
the R51 IT mutation. Bands which were stained with ethidium bromide, ran at 6809, 872 
and 557 bp on a 1,8% agarose gel. Digestion of 168? wildtype plasmid using Pstl 
produces bands at 7681 and 557 bp (figure 5). The Qiagen midi prep kit was used to 
isolate and purify plasmid DNA as instructed. Briefly, R511T transformed E. coli is 
grown overnight in LB containing 100 ug/ul ampicillin. Bacteria is lysed using a 
NaOH-SDS lysing buffer provided with the kit in the presence of RNase A which digests
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liberated RNA. The SDS soluablizes the phospholipid and protein components of the cell 
membrane resulting in lysing of the cell. The NaOH denatures the proteins and both 
chromosomal and plasmid DNA. The lysate is then neutralized by the addition of acidic 
potassium acetate. The high salt concentrations in the neutralizing solution cause 
precipitation of the SDS which traps the larger cell debris, chromosomal DNA and 
denatured proteins. Plasmid DNA being circularized and much smaller than chromosomal 
DNA will renature and remain in solution. The SDS-cell debris complexes are removed 
by centrifuging and the clear supernatant is applied to a pre-equilibrated Qiagen column. 
Resin in the column is an anion-exchange resin which binds DNA under appropriate low 
salt and pH conditions. Plasmid DNA binds the resin and all nonspecific interacting 
metabolites that may be attached to either the plasmid DNA or the resin, are washed away 
with a buffer containing a medium salt concentration. The wash buffer also contains a low 
concentration of alcohol which eliminates nonspecific hydrophobic interactions. The 
pure plasmid is eluted using a high salt containing buffer then desalted and concentrated by 
isopropanol precipitation. Quantification of DNA was performed by 260/280 
spectrophotometer readings, gel and microdot.
R51 IT plasmid DNA was sequenced using and upstream primer E l432 (sequence 
not shown). The sequence confirmed the presence of the desired mutation and absence of 
spurious mutations.
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Plasmid Map 
of R511T
HIV Envelope 
Cleavage site 1 
R to T mutation 
adding 3rd PstI
698
PstI
PCR 3.1 UNI 
+ 168P HIV 
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3374
2502 (added 
site for R511T)
3’
Figure 4. Plasmid map of R51 IT. Site directed mutagenesis^, Stratagene was used to 
introduce the R to T substitution in the cleavage site 1 of 168? HIV envelope. This 
mutation introduced a third PstI restriction endonuclease digestion site. Envelope is 
expressed from the CMV promoter.
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2-3 Cell culture
All cells were maintained at 37® C in a 5% CO2 atmosphere unless otherwise 
described.
Cos 7 ceils (African green monkey kidney cell line) were grown in DMEM 
(Delbecco’s Modified Eagle Medium; Gibco BRL) containing 10% (vol/vol) heat 
inactivated fetal calf serum (PCS) and supplemented with L-glutamine and 
penicillin-streptomycin. Cells are carried to confluency then subcultured so 1 X 10* cells 
populate a T75 flask (10, 56).
U87-CD4-coreceptor (CCR5/CXCR4) cells (Human astroglioma cells) are carried 
in DMEM containing 15% (vol/vol) heat inactivated fetal calf serum (PCS), 
supplemented with L-glutamine, penicillin-streptomycin, genticin (cells were stably 
transduced with the MVT7Neo-T4 retroviral vector and selected for G418 resistance, this 
maintains cell expression of CD4) and puromycin (cells were transduced with 
pBABE-puro-CCR5 or pBABE-puro-CXCR4 and selected for puromycin resistance, this 
maintains cell expression of coreceptor). Cells are subcultured one time per week so 1 X 
10* cells populate a T75 flask. Subcultures are refed eveiy three days (10, 56).
2-4 Envelope Surface Expression by FACS and IFA
In order to determine that R511T is expressed on the surface of transfected cells, 
both PACS (Becton Dickinson PACSCalibur) analysis and immunofluorescence assay 
(IPA) were performed. Briefly, the plasmid encoding expression of the functional R511T 
envelope protein (R511T) was transfected into Cos 7 cells (American type culture 
collection, Manassas, VA) by the PuGENE kit (PuGENE™, Boehringer Mannheim) as 
directed. PuGene is a blend of lipids (non-liposomal formulation) and other compounds in
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80% ethanol. For each transfection of 10̂  cells per 10-cm culture dish, 8 ug plasmid 
DNA is used (R51 IT, 168P or CD4 as a negative control). Transiently expressing Cos-7 
cells were harvested 2 days later using 0.1 mM EDTA in PBS then stained for FACs 
analysis. Each transfected Cos 7 group (R51 IT, 168P and CD4) is divided into 8 separate 
tubes for staining using 8 different primary antibodies (table 1). Primary antibody is 
added at the specified dilution in a volume of 100 ul FACS buffer (IX PBS (Gibco)-2% 
FCS-0.1% sodium azide) for 30 minutes at 4° C. Cells are centrifiiged at 1000 rpm and 
unbound primary antibody is aspirated fi-om cells. To be sure all unbound antibody is 
removed, cells are washed in a volume of 2 ml FACS buffer then resuspended in the 
secondary-FITC conjugated antibody (table 1) in a total volume of 100 ul for 30 minutes 
at 4®C. Unbound secondary antibody is washed fi-om cells. For FACS analysis, cells are 
then resuspended in 300 ul FACS buffer containing propidium iodide (PI) which is taken 
up by dead cells. PI is used to exclude dead cells fi*om the analysis.
Cos 7 cells used in IFA surface screening were transfected with either R51 IT,
168P or no plasmid DNA (Mock) using the calcium phosphate precipitation method 
(10,62). Briefly, Cos 7 cells are seeded at 80% confluency (5 X 10̂  cells/6 cm dish) then 
incubated over night. At 24 hours, in a sterile tube, 10 ug DNA is mixed with CaCb at a 
concentration o f250 mM in a volume 1/20 that of the cell culture. An equal volume of 
2X HEPES (140mM NaCl, 1.5 mM Na2HP0 4 , 50mM HEPES) is added drop wise to the 
DNA/CaCb with mixing followed by a 1.5 minute room temperature incubation. The 
HEPES buffered solution is used to form a calcium phosphate precipitate that is added to 
the 6 cm dish of Cos 7 cells. The DNA precipitate is layered onto the cells and is taken up 
by unknown means. At 12 hours following transfection, precipitate is washed off cells
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and 36 hours after transfection cells are expressing proteins and ready to use in different 
assays.
For the IFA, cells are detached from the 6 cm dish using 0.1 mM EDTA+PBS 
then counted. Cells are seeded at a concentration of 3.5 X 1 O'* cells in a volume of 750 ul 
per chamber in an 8 well chamber slide then incubated overnight. At 24 hours after 
seeding chamber slide, media was aspirated from cells then lid and chamber partition was 
removed from the chamber slide. Cells were washed with media then protied using the 
envelope specific antilx>dy HIVIG (dilution of 1:100 corresponding to polyclonal HIVIG 
concentrations of 16 mg/ml) in a total volume of 70 ul per chamber then incut)ated under 
humidifying conditions at 37 ® for 30 minutes. Chaml>er slide was washed 3 times with 
warm media then probed using FITC conjugated Goat anti-human IgG antibody (dilutions 
of 1:100 corresponding to concentrations of FITC conjugated Goat anti-human IgG at 
1 mg/ml) in a volume of 70 ul per chamber. Chamber slide was incubated in a humidifying 
chamber at 37® for 30 minutes then washed 4 times with IX PBS containing Mg^ and 
Ca^. The divalent cations are added to help cells stay adhered to the slide. After wash is 
aspirated from the cells, they are then fixed with 1% formaldehyde in PBS for 15 minutes 
at room temperature. Chamber slide was rinsed one time in IX PBS containing Mg^ 
and Ca"  ̂then fixed with "20 degree acetonezmethanol (1:1) for 5 minutes at room 
temperature and dried. Stained cells were viewed by epifiourescence microscopy.
FACS staining panel
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Primary antibody Primary antibody 
epitope
Primary antibody 
dilution or amt.
Secondary antibody
human gamma 
globulin
negative control 1:350 goat anti-human 
IgG-FITC
m v iG polyclonal
anti-envelope
1:200 goat anti-human 
IgG-FITC
F240 anti-env 1 ug goat anti-human 
IgG-FITC
257D mV-1 MN V3 1 ug goat anti-human 
IgG-FITC
negative control goat anti-human 
IgG-FITC
Murine IgG negative control 1:100 goat anti-mouse 
IgG-FITC
58.2 m v -1  MN V3 
Murine IgGi
1:100 goat anti-mouse 
IgG-FITC
59.1 HIV-1 MN V3 
Murine IgG,
1:100 goat anti-mouse 
IgG-FITC
Table I. Staining panel for indirect fluorescence staining for FACS analysis. Both 58.2 
and 59.1 are mAh from mice immunized with HIV-1 MN V3 peptide sequence (57). F240 
is a human mAh isolated from an infected HIV-1 individual (58). 257D is a human mAh 
IgGl to the HIVmn V3 (61)
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2-5 Envelope Functional Assays:
2-5a. Fusion Assay
Cell-cell fusion is one method used in HIV research to analyzed envelope protein 
function. Cos 7 cells were transfected using R51 IT, 168P and Mock plasmids by the 
calcium phosphate precipitation method described in IFA. At 12 hours after Cos 7 cells 
are transfected, U87-CD4-CCR5 cells are detached from the T75 flask using 0.25% 
trypsin and seeded into wells of a 96 plate. The U87-CD4-CCR5 cells are seeded at a 
concentration of 5X10^ cells/well then incubated overnight in 150 ul DMEM + 10%
PCS. At 36 hours after transfection of Cos 7 cells, they are detached from the 6 cm dish 
with 0.5 mM EDTA+PBS for 10 minutes. Cos 7 cells are centrifiiged to pelleted cells for 
5 minutes at 1000 rpm. Media is aspirated and the pellet washed 1 time to removed any 
EDTA which could chelate divalent cations interfering with cell-cell fusion or adhesion. 
Cells are resuspended in warm media then seeded into the same wells of the 96 well plate 
the U87-CD4-CCR5 are seeded in from the previous day at the same concentration of 5 
X 10̂  cells/well. Transfected Cos 7 cells are also cells on the fixed 96 well plate are dry, 
they are stained for HIV envelope expression.
For staining, cells are prewetted with PBS then probed with the 1:250 dilution 
corresponding to HIVIG concentrations of 16 mg/ml in wash buffer (PBS +2% PCS). 
Staining was done in a total volume of 70 ul/well. Plates were incubated for 30 min at 37 
® C then unbound HIVIG was washed out of wells using wash buffer. The secondary 
antibody was added at dilutions of 1:100 corresponding to anti-human 
phosphate-conjugated IgG concentration of 1 mg/ml in wash buffer for 30 min at 37 ° C. 
Staining solution from KPL kit (Kirkegard & Perry laboratories) is mixed into two
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separate tubes. Tube 1 contains 0.5 ml buffered substrate solution in 4.5 ml deionized 
water and tube 2 contains 100 ul phthalo red solution mixed with 100 ul activator 
solution. Both tubes incubate at room temperature for five minutes at which time the 
secondary antibody is washed fi-om the plate using deionized water. Tube 1 and 2 are 
mixed after the 5 minute incubation then 100 ul of substrate is added to each well and 
incubated at room temperature until color appears. Substrate is washed ofiT with deionized 
water and then the plate is air dried. Transfection efficiency is determined by the 
percentage of stained Cos 7 cells in non-cocultured wells. In cocultured wells, positive 
fusion between U87-CD4-CCR5 and Cos 7 cells is determined by microscopically 
counting stained syncytia (figure 13).
2-Sb. Vaccinia Virus- lac Z reporter fusion Assay
The T7 RNA polymerase gene fi-om bacteriophage was ligated to a vaccinia virus 
transcriptional promotor, P7.5, then integrated into the vaccinia virus genome. When 
cells are infected with this recombinant vaccinia virus (vTF7-3), T7 RNA polymerase is 
synthesized in the cytoplasm of infected host cells where vaccinia replicates. One 
advantage for using the T7 RNA polymerase is it has strict promotor specificity. A 
second recombinant vaccinia virus (vCB21R-lac Z) was made by ligating the 
y^galactosidase gene to the bacteriophage T7 promoter. When Cos 7 cells are infected 
with vCB21R-lac Z alone, no y^galactosidase is made. When both recombinant viruses 
wind up in the same cytoplasm then T7 RNA polymerase binds the T7 promotor and 
/^galactosidase is synthesized. These two recombinant vaccinia viruses can easily be 
employed to detect fusion between two or more cells when one group of cells is infected 
with vTF7-3 and the other is infected with vCB21R-lac Z (55).
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Four separate dishes of Cos 7 cells were transfected with R51 IT, 168P, CD4 as a 
negative control and one dish was cotransfected with CD4 and CCR5 using the FuGENE 
kit as described above in FACS. At 36 hours after transfection when cells are expressing 
the most protein, transfected cells are infected with one of the two different recombinant 
vaccinia viruses. The envelope expressing transfected cells were infected with 
vCB21R-lac Z (NIH Repository). The cotransfected cells expressing CD4/CCR5 were 
infected with recombinant vaccinia vTF7-3 (NIH Repository). Media was aspirated from 
cells after 3 hours of infection at multiplicity of infection (MOI) of 5 and washed with IX 
PBS containing Mg^Ca^. Cells were then detached from dishes using 0.1 mM 
EDTA-PBS and cocultured together at a total concentration of 2 X 10̂  cells in equal 
parts in a 96 well V-bottom plate for the Galacto-light Assay. Fusion is similar to the 
fusion assay except fusion is detected by y^galactosidase activity. Cells were plated with 
and without viral inhibitors to limit cytopathetic effect (CPE) which would make results 
unreadable. (Rifampicin which inhibits assembly of DNA and protein into mature virus 
particles, and AraC which inhibits vaccinia virus DNA replication and late-gene 
expression.) When cells expressing T7 RNA polymerase fiise with cells containing the lac 
Z gene linked to the T7 promotor, y^galactosidase is produced. Cells were cocultured 
for 0.5, 1,2, and 3 hours to determine fusion kinetics. Cells are then lysed and incubated 
with reaction buffer containing Galacton substrate. This substrate is cleaved into the 
active light emitting form by y^galactosidase. At 1 hour light emission accelerator is 
added which terminates the enzyme activity and accelerates light emission 
(Galacto-Light™ chemiluminescent reporter gene assay system for the detection of
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p-galactosidase). Signal is read as relative light units (RLU) in the luminometer (Tropix 
TR 717, microplate luminometer).
2-Sc. Pseudotype Assay
In the pseudotype assay, Cos 7 cells are cotransfected with a plasmid containing 
the entire HIV genome that contains a non-functional envelope gene and a second plasmid 
containing the envelope gene to be studied. The virion produced from this 
co-transfection packages an NL-ThyDB-sv genome and expresses the envelope from the 
envelope plasmid. If the envelope expressed is functional then these virions are infectious 
for one round of infection. Prodigy virions do not have envelope proteins on their 
surface.
Cos 7 cells were transfected using the calcium phosphate method described for the 
fusion assay with modifications. A total of 10 ug DNA is used with 3 ug ENV containing 
plasmid and 7 ug NL-ThyDB-sv backbone (37). At 36 hours after transfection, a 96 well 
plate is seeded with 1 X lO'* U87-CD4-CXCR4 cells/well as described for the fusion 
assay. Cells are incubated overnight at 37 ® C to adhere to the plate. At 60-72 hours after 
transfection, media containing the pseudotype virions is drawn off the co-transfected Cos 
7 cells then filtered through 0.2 pm syringe filter. Media is aspirated from the 
U87-CD4-CXCR4 cells in the 96 well plate then cell free pseudotype supernatant is 
added at dilutions containing 50 and 100 ul of cell free pseudotype supernatant in a total 
volume of 150 ul. U87-CD4-CXCR4 cells are then incubated in the presence of 
pseudotype virions overnight at 37 ® C. Supernatant is aspirated and cells washed 1 time 
in IX PBS then fixed with methanokacetone (1:1) for 10 minutes at -20 ° C. The
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methanol:acetone is aspirated and the cells are dried. Cells were stained by indirect 
staining using the Human ABC kit (biotech™) as directed. The primary antibody was 
diluted at 1:100 correlating to HIVIG concentrations of 16 mg/ml. The secondary 
antibody (biotin conjugated anti-human IgG) was diluted as instructed in the kit followed 
by strepavidin peroxidase and detected by DAB substrate. Pseudotype virion infected 
cells stain brown and are counted microscopically as infected cells/well.
2-6. Western Blots from Transfected Cos 7 Cells, lysate and supernatant 
2-6a. Lyse Cells
Cos 7 cells are transfected using the calcium phosphate method as described in the 
fusion assay. Thirty six hours after transfection, supernatant is drawn oflF cells and filtered 
through 0.2 pm filter then saved on ice for immunoprécipitation. Cells are washed 2 X 
with ice cold PBS+0. ImM CaCb 1 OmM Mg^Cl^. One half ml Lysing buffer (1% 
triton-XlOO, 50mM Tris pH 7.5 + 150 mM NaCl) is added to each 6 cm transfected Cos 7 
cell dish and incubated on ice for 15 minutes. Cells are then scraped fi*om the plates with 
a rubber policeman and transferred to a 1.5 ml eppendorf tube and incubate 10 more 
minutes on ice. Cell debris is removed by centrifuging lysates at 14000Xrpm @ 4 ® C for 
15 minutes. Supernatants are transferred to a new tube and pellet is discarded.
2-6b. Immunoprécipitation
Cell lysates and supernatant are precleared of nonspecific protein A sepharose 
(PAS) binding proteins by adding 50 ul PAS (Sigma) for 30 min at 4 ® C with rocking. 
Preclearing PAS is removed by centrifuging at 14000Xrpm for 1 minute then supernatant 
and cell lysates are transferred to a new tube and PAS pellet is discarded. To each tube, 5 
ul of 1.6 mg/ml HIVIG polyclonal antibody is added then tubes are incubated 1 hour on
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ice. Forty ul PAS is then added to each tube with rocking for 1 hour at 4 ° C. PAS binds 
the FC receptor of HIVIG which is specifically binding ENV in supernatants or cell 
lysates. Centrifuging at 14000Xrpm pulls down the PAS-HIVIG-ENV complex then 
supernatant is aspirated. PAS-HIVIG-ENV complex is wash 4 X with lysing buflFer, then 
envelope is eluted with 50 ul of 2 X SB + DTT (59) and boiling for 3-5 minutes. PAS is 
again centrifuged and supernatant containing envelope protein is ran on sodium dodecyl 
sulfate polyacrylamide gel elecrophoresis (SDS-PAGE).
2-6c. SDS-Page and Western Blot
Each sample was separated by SDS-PAGE performed using a modification of the 
tris-glycine discontinuous system of Laemmli (1970). Proteins were transferred to a 
nitrocellulose membrane (Microns separation Inc., Westborough, MA) by immunoblotting 
in Transfer buffer (0.037% SDS, 48mM Triz base, 39mM glycine, 20% methanol) at 
0.35 amp for 2 hours using a Bio-Rad mini trans-blot cell. The blots were block in 10% 
milk-PBS-0.5% tween-20 then probed with murine 50.1 anti-V3 loop antibody. A 
secondary IgG antibody, anti-mouse-avidin was used to probe primary antibody then 1 
mg/ml strepavidin peroxidase fi-om murine ABC kit (Biostain™, Biomedia) at 1/5000 
dilution in wash buffer was used to bind avidin. Bands were detected through ECL 
chemiluminescence used as instruction.
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3. RESULTS
3-1. Mutation Analysis
The linear amplification product, R511T contained the mutation AGA to ACT 
changing R at amino acid 511 to T and added a new Pst\ site. Plasmids were isolated 
then digested with PstI and analyzed by agarose gel. Three bands corresponding to 6809, 
872 and 557 base pairs (bp) were present. Pst\ digestion of wild type plasmid 168 P 
produced expected bands corresponding to 7681 and 557 (bp) (Figure 5). Sequence 
data confirmed that R51 IT matched the wildtype sequence surrounding the cleavage site 
except for the engineered nucleotide changes (figure 6a, 6b).
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1.8% Agarose Gel of Pst\ digestion of R511T and 168P
Fig 5. The 168P wildtype and R511T plasmids were digested with PstI and 
electrophoresed on 1% agarose gel. (Lane 1) R51 IT showing bands at 6809, 872 and 
557 bp. (Lane 2) 168P showing bands at 7681 and 557 bp as predicted for both 
constructs. (Lane 3) Molecular weight markers, expressed in kilodaltons (kDa).
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Mutant R511T Construction
g p l2 0
si/
cleavage
site gp41
\|/
5’- AGAGAA AAA AGA -3’ GC4GTGG GAATAGGAGT TTTGTTC-3’
(Top)
(168P) R E K R
5’-GAGTGGTGCAG AGAGAA AAA AÇT 
(Middle)
(R511T) R E K T 
(5’-GGAACAAAAC TCCTATTCCC ACTGC
(Bottom)
GC4GTGG GAATAGGAGT TTTGTTC-3’
AG TTTTTCTCTCTG CACCACTC-3’)
Figure 6a. Construction of the R51 IT Mutant. The nucleotide sequence of 168P 
wildtype envelope (top) and R51 IT mutant envelope (middle) with corresponding amino 
acid sequence at cleavage site 1. Mutation is indicated, AGA to ACT changing R to 
T. Both complete oligonucleotide primer sequences used in substitution reaction (middle 
and bottom sequences) are shown. Added Pstî site across the cleavage site is indicated in 
bold italic print.
Chromatogram
iÂĈ AGTGGTGĈ  ̂AG AGA G< AG I A A r AQG V TG
Figure 6b. Chromatogram from sequencing using the E l432 primer (primer sequence not 
shown) located upstream from the mutation. ACT change shown after the string of 5 A 
nucleotides in sequence near 230.
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3-2. Western Blot analysis of wild type and RSI IT mutation in Cos 7 Cells
Both transfected Cos 7 cell lysate and syringe filtered supernatant were 
immunoprecipitated then run on a 6% SDS-PAGE gel containing a 4% stacking gel. The 
gel was blotted as described in materials and methods. 168? wild type cell lysate produced 
immunoreactive bands corresponding to the external glycoprotein (gpl20) and the 
precursor polypeptide (gp 160). In all cases, gpl20 was produced in equal or greater 
amounts than gpl60. R51 IT cell lysate produced one major immunoreactive band 
corresponding to the precursor polypeptide (gpl60) and an immunoreactive band less than 
10% of the gpl60 signal corresponding to gpl20. It is possible that cleavage seen at site 
2 is not inhibited. Mock transfected cells produced no immunoreactive bands, (figure 7a.)
168? wild type supernatant produced an immunoreactive band corresponding to 
shed gpl20. R51 IT supernatant produced little to no band corresponding to gpl20 and 
mock ceU lysates produced no immunoreactive bands, (figure 7b.)
Transfection efficiency of 168? was 30% and R511T was 31% as determined by 
microscopic observation of alkaline-phosphate stained cells. Approximately equal 
amounts of protein were produced in each transfected group of cells as determined by 
western blots.
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Western blot of 168P, R511T and Mock 
Transfected cell lysates
y  2 5 ;
gpl20
Figure 7a. Western blot o f transfected Cos 7 cell lysate, probed using indirect staining 
described in this sequential series: Murine 50.1 (anti-V3 antibody), anti-mouse-biotin 
antibody, then avidin-HRP followed by ECL chemiluminescence. Immunoreactive bands 
are seen corresponding to gpl60 and gpl20 in the 168P wild type lane and gpl60 in the 
R51 IT lane. Mock lane shows no immunoreactive bands. Soluble gpl20 is used as a 
marker.
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Western blot of 168P, R511T and Mock 
Transfected cell supernatants
t
gpl60
gpl20
00 I H
§
tos
Figure 7b. Western blot of transfected Cos 7 cell supernatant, probed using indirect 
staining described in this sequential series: Murine 50.1 (anti-V3 antibody), 
anti-mouse-biotin antibody, then avidin-HRP and detected by ECL chemiluminescence. 
Immunoreactive bands are seen corresponding to shed gpl20 in then 168? wild type lane 
and a weak gpl20 in the R51 IT lane that may be due to cleavage at site 2. Mock lane 
shows no immunoreactive bands. Soluble gpl20 is used as a marker.
34
3-3. Detection of Envelope surface expression From FACS and IFA
Transformed Cos 7 cells were stained for surface expression of HIV envelope 
using indirect staining as described in the materials and methods. The primary anti-HIV 
envelope antibodies and secondary FITC labeled antibodies used in staining cells for 
FACS analysis are listed in Table 1. Propidium iodide (PI) is added to the samples to stain 
dead cells. When setting parameters with the FACS for analyzing cells, any PI stained 
cells are not included. With help from Joann York, samples of live stained cells are 
analyzed by FACS. Each cell is measured by FACS for its size (foreword light scatter), 
granularity (90° light scatter) and fluorescence. Cells are separated into stained and 
unstained populations due to their particular fluorescent brightness. If the population has 
a subpopulation expressing HIV envelope, a second right shifted peak is seen. Analysis 
of 168P and R51 IT transfected Cos 7 cells showed that both had subpopulations that 
were expressing HIV envelope on the surface as shown by a second right shifted peak 
(figure 8). When stained with the FITC conjugated secondary antibody alone no second 
right shift peak was detected suggesting all staining was envelope specific. CD4 
transfected cells served as a negative control and did not show right shifting 
subpopulations in any staining (figure 8).
Envelope surface expression on both R51 IT and 168P transfected Cos 7 cells was 
shown on adherent, non-permeablized cells by IFA. Mock transfected cells showed no 
staining (figure 9). Sodium Azide which is an energy inhibitor and indirectly inhibits 
endocytosis was not added to solutions so surface expression could not be determined 
from these experiments alone.
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Surface expression of HIV Envelope 
by FACS Analysis
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Figure 8. 168P and R511T transfected Cos 7 cells expressing HIV envelope. Staining 
for surface envelope was done using the envelope specific primary antibodies HIVIG, 
F240, 257D, 58.2 and 59.1 followed by a FITC conjugated secondary anti-primary 
antibody. Compensation was set to exclude dead cells from analysis using propidium 
iodide. Antibodies not specific for HIV envelope (human gamma globulin, murine IgG 
and goat anti-mouse IgG-FITC) did not show a right shift in population suggesting 
envelope specific staining. (Top row) Wild type expressing cells. (Middle row) R511T 
expressing cells. (Bottom row) CD4 expressing cells used as the negative control which 
did not show Envelope specific right shifts in populations as expected.
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Immunofluorescence Assay
Figure 9. 168P, R511T or Mock transfected Cos 7 cells using indirect staining for 
surface expression of envelope protein. Envelope specific HIVIG antibody was followed 
by anti-human-FITC conjugated antibody then viewed at 40X on a epifluorescence 
microscope, (top) 168P wildtype, (middle) R51 IT and (bottom) Mock transfected cells. 
During photo processing Mock was exposed for a longer time in order to see cells. 
(Notice background is lighter) Mock cells did not appear stained.
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3-4. R51 IT Pseudotype Infectivity
Virions expressing R51 IT envelope protein as described in materials and methods 
were not infectious. Infectivity was determined by microscopic counting of stained cells 
per weU. In 50 ul supernatant wells containing 168? pseudotype virions (1:3 dilution 
wells) incubated on U87-CD4-CXCR4 cells, 87 infected cells were counted. R51 IT 
pseudotype virions produced no infected cells at the 1:3 dilution. In 100 ul supernatant 
wells containing 168? pseudotype virions (2:3 dilution wells) incubated on 
U87-CD4-CXCR4 cells, 190 infected cells were counted. R51 IT pseudotype virions 
produced one stained cell at the 2:3 dilution. Mock transfected cell supernatant 
produced no stained cells at either dilution, (figure 10)
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Pseudotype Assay 
168P, R511T  and Mock
Envelope expressing  virions
I68P RSI IT Mock 
Pseudotype envelope virions
H  2:3 din of 
pseudotype 
supernatant
ED 1:3 din of 
pseudotype 
supernatant
Figure 10. Pseudotype virion expressing 168? envelope infected 190 U87-CD4-CXCR4 
cells at the 2:3 dilution and 87 U87-CD4-CXCR4 cells at the 1:3 dilution. Pseudotype 
virion expressing R51 IT produced one infected U87-CD4-CXCR4 cell at the 2:3 
dilution. Mock supernatant on U87-CD4-CXCR4 produced no infected cells.
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3-5. R511T fusion activity in the fusion assay
It was shown that R51 IT envelope did not support fusion by both the fusion assay 
and the vaccinia lacZ reporter assay. Transfected Cos 7 cells were allowed to cocultivate 
with U87-CD4-CCR5 partners in the fusion assay for 3, 5 and 24 hours before fixing and 
staining for envelope expression. Only multinucleated cells that stained for envelope 
expression were counted as positive syncytia (figure 11) The number of nuclei per stained 
syncytia were also counted by eye microscopically (figure 12). Wild type 168P envelope 
increased both number of syncytia per well and the average number of cells involved in 
syncytia formation over time. R5IIT maintained a low number of syncytia with a slight 
increase at 24 hours with little to no increase in number of cells involved in syncytia.
Mock transfected cells produced no stained syncytia (figure 13). Transfection efficiency 
for 168P transfected Cos 7 cells was 31 % and for R511T 30%.
40
Fusion Assay 
168P, R511T and Mock transfected  Cos 7 
co-cultured with U87-CD4-CCR5 cells
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Figure 11. Transfected Cos 7 cells expressing 168P, R51 IT or no envelope (mock) on 
their surfaces were cocultured over a time coarse with U87-CD4-CCR5 cells then fixed 
with acetonermethanol (1:1). Cells were stained indirectly using HIVIG as the primary 
antibody followed by anti-human alk-phos conjugated antibody. Only multinucleated cells 
staining for envelope were counted as positive syncytia. Wells containing 168P expressing 
Cos 7 cells cocultured with U87-CD4-CCR5 cells increased the number of syncytia 
detected over time where R51 IT and Mock expressing cells did not.
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Figure 12. Transfected Cos 7 cells expressing 168P, R511T or no envelope (mock) were 
cocultured over a time coarse with U87-CD4-CCR5 cells then fixed with 
acetone:methanol (1:1). Only multinucleated cells staining for envelope were counted as 
positive syncytia. The average number of nuclei per syncytia were counted. The 
number of cells recruited into the 168P wildtype syncytia increased over time. The 
number of cells recruited into the R51 IT mutant syncytia did not increase over time.
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Staining for Syncytia in 168P, R51 IT and mock 
Transfected Cos 7 cells
Figure 13. 168P, R51 IT or Mock transfected Cos 7 cells cocultured with 
U87-CD4-CCR5 cells in the fusion assay. Coculture of mock transfected cells (top),
R51 IT envelope expressing cells (middle) and 168? wildtype envelope expressing cells 
(bottom). All cocultures are stained with the alk-phos kit using HIVIG as the primary 
envelope specific antibody. R51 IT expressing cells stain for envelope expression but are 
not forming syncytia. 168? stain for envelope expression and form syncytia.
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3-6 Vaccinia virus Lac Z reporter system
R511T envelope proved to be fusion defective in the vaccinia Lac Z reporter assay 
described in materials and methods. Wild type envelope expressing lac Z cells cocultured 
with CD4/CCR5 T7 RNA polymerase expressing cells, showed 154 fold increase in RLU 
over time (table 2). 168P envelope expressing cells alone showed a background of 5.5 
fold increase in RLU. R5IIT envelope expressing lac Z cells cocultivated with 
CD4/CCR5 T7 RNA polymerase expressing cells showed a 7 fold increase in RLU over 
time. 168P envelope expressing cells infected with a recombinant vaccinia virus that 
produces CD4/CCR5 and y^galactosidase was used as a positive control along with wells 
containing pure /^galactosidase. Lysis buffer and single transfected Cos 7 ceUs infected 
with recombinant virus provided negative controls (figure 14). Transfection efficiencies 
for 168P wild type ceils was 44 % and R51 IT was 40 %.
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Vaccinia virus iacZ re p o rte r  assay
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CD4/CCR5 rV-17
Figure 14. y^galactosidase is made in cells expressing envelope that supports fusion as in 
168P envelope. R51 IT envelope did not support fusion therefore y^galactosidase was not 
produced. Fused cells produce y^galactosidase which hydrolyzes the substrate that is 
detected in RLU.
Vaccinia LacZ reporter assay RLU
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Plasmid RLU at 30 
minutes
RLU at 1 hr RLU at 2 hr RLU at 3 hr
Cos 7 168P Env 27 82 633 4128
rV-LacZ + Cos 7 
CD4/CCR5 rv-17
27 79 644 4209
Cos 7 R51 IT Env 31 39 65 211
rV-LacZ + Cos 7 
CD4/CCR5 rv-17
28 34 69 211
Cos 7 168P Env 33 43 81 177
rV-LacZ 33 53 88 186
Cos 7 R51 IT Env 28 35 73 NA
rV-LacZ 30 30 73
Cos 7 168P Env 9757 26218 99630 165965
rV- CD4/CCR5 9746 26283 99838 166476
Cos 7 CD4/CCR5 29 31 31 NA
rV-17 30 32 29
Beta- 1978828 1997068
galactosidase 1983157 2001904
control
Lysis buffer 11 17 15 39
control 13 18 29 35
Table 2. /?-galactosidase is synthesized when 11 promotor-lac Z containing cells fuse 
with cells carrying the 11 RNA polymerase, y^galactosidase hydrolyzes substrate 
(galatco-light) and is detected as RLU in luminometer. Tests were performed in duplicate 
wells.
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4. DISCUSSION
Between 1981-1999 an estimated 16.6 million deaths have been attributed to 
AIDS, 10 million people are currently living with AIDS and 23.4 million people are living 
with HIV infection. (3,50) Each new infection added to the ever rising statistics is a 
constant reminder for the urgent need to develop an effective, safe and affordable 
vaccine.
The main focus for HIV vaccine studies has been on the envelope protein due to 
the important role it plays in binding and entry events. The crystallization of gpl20 
revealed the structure and showed the most conserved, stable structures are at the 
bottom of clefts or behind sugar molecules hidden fi’om the immune system. Neutralizing 
antibody targets are revealed only for brief moments due to conformational changes as 
the Envelope binds to CD4 and coreceptor (3). A recent ‘‘fusion competent” HIV vaccine 
captured these transient structures that arise during binding and entry, then were used to 
immunize transgenic mice. Antibodies were produced capable of neutralizing inactivity 
of 23 out of 24 primary HIV isolates (10).
The focus of the present study was to develop and characterize the cleavage 
defective envelope (R51 IT). This cleavage defective envelope arrests binding events at an 
undefined point before the pre-hairpin intermediate is formed (figure 2 ). Pst\ digestion 
and sequencing of the mutated region confirmed that R at amino acid 511 was changed to 
T and no undesired mutations were present.
R51 IT envelope was expected to be fusion defective because the N-terminis of 
gp41 (still attached to the C-terminis of gpl20) would be physically unable to insert into 
the host cell plasma membrane. A negative outcome in the fusion assay could be due to
47
no surface expression of envelope as well as a fusion defective protein. It was important 
to show cell surface expression of this mutant RSI IT envelope to determine if that protein 
was indeed fusion defective. The two methods used to confirm surface expression of 
RSI IT envelope on transfected Cos 7 cells was FACS and IFA.
Specific experiments showing surface expression of envelope on the pseudotype 
virion were not performed. Cells that are co-transfected with the NL-ThyDB-sv plasmid 
and envelope plasmid would be producing products fi’om both plasmids. It was shown 
that envelope transfected Cos 7 cells express the envelope on the surface of the cell. In 
co-transfected cells, the full-length of NL-ThyDB-sv HIV RNA would be complexed with 
capsid proteins and transferred to the cell surface membrane at these envelope containing 
sites. It would be unlikely that the NL-ThyDB-sv virion would bud fi'om the surface of 
the cell and not pick up envelope proteins that are on the surface.
It was shown by the fusion assay and confirmed through the vaccinia virus lacZ 
reporter assay that R51 IT envelope is non-fimctional in cell-cell fusion. The pseudotype 
assay confirmed R511T envelope is noninfectious on the surface of virions.
It had been shown previously that this mutation in a different HIV envelope isolate 
could be pulled down using CD4 covalently attached to sepharose beads in a competitive 
fashion (53). This evidence suggests binding events are arrested after the mutant envelope 
binds to CD4 and before fusion occurs. Experiments could be designed for our HIV 
envelope isolate mutant to both confirm binding of R5l IT to CD4 and narrow the point 
where R51 IT is arrested in the current model of binding and entry events (figure 2). An 
s-peptide tagged CD4 which is pulled down using s-agarose could be used to confirm 
R511T binding to CD4. Likewise, an s-peptide tagged coreceptor can be used to show
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R51 IT involvement with the coreceptor. Similar experiments have shown gpl60 can be 
pulled down after binding CD4 and the s-peptide tagged coreceptor. This evidence 
suggests R51 IT could also be pulled down using the s-peptide tagged coreceptor. 
Interaction between R511T, CD4 and coreceptor would expose the transient epitopes 
within the complex of interacting proteins, possibly catching those epitopes which have 
proved to be neutralizing. This is in sharp contrast to a non-ftmctional envelope that is 
static and does not interact with CD4 and coreceptor giving the same negative results in a 
fusion assay.
Because R51 IT is cleavage defective, it does not have the capacity to obtain a 
pre-hairpin intermediate structure (figure 2) therefore fi*eezing binding events at an 
undefined point before the pre-hairpin formation. There is evidence that gpl60 
undergoes conformational changes similar to the mature envelope. Studies of an 
inhibitory peptide which can bind to a sequence on gp41 exposed only after CD4 and 
coreceptor binding, also bind to gpl60 under the same conditions. This suggests 
wildtype envelope and gpl60 both undergo a similar pattern of conformational changes 
upon forming complexes. Though it is unclear at which point in binding events this 
inhibitory peptide site becomes exposed, it can bind both gp41 and gpl60 suggesting this 
site becomes at least partially exposed prior to the pre-hairpin intermediate (38).
Western blots of IP cell lysates and supernatant fi'om R51 IT transfected Cos 7 
cells confirmed that R51 IT protein was cleavage defective. Cell lysates containing R51 IT 
protein produced one major immunoreactive band consistent with gp 160 as expected.
A second immunoreactive band was seen consistent with gpl2Q at a significantly reduced 
amount in both the R511T cell lysate and supernatant. One explanation for this
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unexpected gpl20 band is mutating R to T at site 511 did not completely inhibit cleavage 
at site one. Evidence from the fusion assay and Vaccinia virus lacZ reporter assay do not 
support this explanation. A more likely explanation is mutating R to T at site one did not 
affect the 10-20% of normal cleavage that takes place at site two. Evidence from the 
fusion assay suggest this is true because cleavage at site two produces biologically inactive 
surface envelope proteins. This explanation also supports the observance of a significantly 
reduced amount of gpl20 seen in both lysates and supernatants from mutant transfected 
cells.
To support this explanation, polyclonal antibodies could be developed against the 
peptide sequence between 502-516 (16). These polyclonal antibodies would bind gpl20 if 
cleavage occurred at site one and would bind to gp41 if cleavage occurred at site two.
A formaldehyde fixed, fusion competent vaccine catching R511T in different 
conformations leading up to the point where binding events stop, make it possible to map 
critical neutralizing epitopes if they arise. A non-formaldehyde fixed, fusion competent 
vaccine with R511T would show whether neutralizing epitopes arise at the specific point 
where binding is arrested. If critical neutralizing determinants arise, this same mutation 
can be incorporated into the vaccinia virus insertion vector made by Therion. This 
vaccinia virus insertion vector contains the 168P envelope gene (pAbT4587-168Penv) and 
is more suitable for clinical development of human vaccines if critical neutralizing epitopes 
are identified.
If the critical neutralizing epitopes are not identified from either formaldehyde or 
non-formaldehyde fixed fusion competent vaccines, it suggests they arise at a point later in 
binding and entry events. It cannot be ruled out that this mutation is placed within the
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critical neutralizing epitope, masking its immimogenicity. Further mutational studies are in 
progress that arrest the binding events at later time points from where the R51 IT mutation 
arrests these events. When the critical neutralizing epitopes are found it will be possible to 
determine if this mutation falls within that epitope.
In summary, the mutation at amino acid 511 changing R to T produces a cleavage 
defective HIV envelope (gpl60). This mutated envelope arrests the process of binding 
and entry, possibly trapping critical neutralizing epitopes which can be used for a future 
vaccine candidate.
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